IL-33 represents an attractive therapeutic target for COVID-19 because increased IL-33 levels might facilitate excess lung inflammation in patients hospitalised with COVID-19 and serum IL-33 levels correlate with poor clinical outcomes [31, 32]. The gene discussed is IL33; the disease is COVID-19.